Four subtypes of cHL are shown below. CD30 is expressed in approximately 95% of all cases of cHL.2
cHL Subtype
Description
CD30 Expression
Nodular sclerosis cHL
Characterized by collagen bands that surround at least 1 nodule and by HRS cells with lacunar-type morphology.3
94%4
Mixed cellularity cHL
Characterized by classic HRS cells in a diffuse mixed inflammatory background.5
100%4
Lymphocyte-depleted cHL
A diffuse form of cHL rich in HRS cells and/or depleted of non-neoplastic lymphocytes. Histiocytes are usually abundant.6
100%4
Lymphocyte-rich cHL
Characterized by scattered HRS cells and a nodular or diffuse cellular background consisting of small lymphocytes, with an absence of neutrophils and eosinophils.7
100%4
CD30 is a hallmark of the diagnosis of systemic anaplastic large cell lymphoma (sALCL) and is variably expressed in other peripheral T-cell lymphomas (eg, PTCL-NOS, AITL).1,8
There are approximately 30 different subtypes of CD30-expressing PTCLs.9
PTCL Subtype
Description
CD30 Expression
Systemic anaplastic large cell lymphoma (sALCL), ALK+
Large lymphoid cells with abundant cytoplasm and pleomorphic nuclei. Chromosomal translocation involving ALK gene and expression of ALK protein and CD30.10
100%11
Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS)
Heterogeneous category of nodal and extranodal mature T-cell lymphomas that do not correspond to any specifically defined entities of mature T-cell lymphoma.12
~60%13
Angioimmunoblastic T-cell lymphoma (AITL)
Neoplasm of mature T follicular helper cells characterized by systemic disease and a polymorphous infiltrate involving lymph nodes.14
~75%13
Adult T-cell leukemia lymphoma (ATLL)
Mature T-cell neoplasm most often composed of highly pleomorphic lymphoid cells. Usually widely disseminated. Caused by the human retrovirus HTLV-1.15
~25%16,17
Enteropathy-associated T-cell lymphoma (EATL)
Neoplasm of intraepithelial T cells occuring in individuals with celiac disease. Exhibits varying degrees of cellular pleomorphism.18
~55%13,19
Mycosis fungoides
Characterized by infiltrates of small- to medium-sized T lymphocytes with cerebriform nuclei.20
~10%21
Primary cutaneous anaplastic large cell lymphoma (pcALCL)
Composed of large cells with an anaplastic, pleomorphic, or immunoblastic cytomorphology.22
100%11
Extranodal natural killer (NK)/T-cell lymphoma
Characterized by vascular damage and destruction, prominent necrosis, cytotoxic phenotype, and association with Epstein-Barr virus.23
~50%13,24
ALK = anaplastic lymphoma kinase.
BOXED WARNING
PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML): JC virus infection resulting in PML and death can occur in ADCETRIS-treated patients.
Contraindication
ADCETRIS concomitant with bleomycin due to pulmonary toxicity (e.g., interstitial infiltration and/or inflammation).
Warnings and Precautions
Most Common (≥20% in any study) Adverse Reactions
Peripheral neuropathy, fatigue, nausea, diarrhea, neutropenia, upper respiratory tract infection, pyrexia, constipation, vomiting, alopecia, decreased weight, abdominal pain, anemia, stomatitis, lymphopenia, and mucositis.
Drug Interactions
Concomitant use of strong CYP3A4 inhibitors or inducers has the potential to affect the exposure to monomethyl auristatin E (MMAE).
Use in Specific Populations
Moderate or severe hepatic impairment or severe renal impairment: MMAE exposure and adverse reactions are increased. Avoid use.
Advise males with female sexual partners of reproductive potential to use effective contraception during ADCETRIS treatment and for at least 6 months after the final dose of ADCETRIS.
Advise patients to report pregnancy immediately and avoid breastfeeding while receiving ADCETRIS.
BOXED WARNING
PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML): JC virus infection resulting in PML and death can occur in ADCETRIS-treated patients.
Contraindication
ADCETRIS concomitant with bleomycin due to pulmonary toxicity (e.g., interstitial infiltration and/or inflammation).
Warnings and Precautions
Most Common (≥20% in any study) Adverse Reactions
Peripheral neuropathy, fatigue, nausea, diarrhea, neutropenia, upper respiratory tract infection, pyrexia, constipation, vomiting, alopecia, decreased weight, abdominal pain, anemia, stomatitis, lymphopenia, and mucositis.
Drug Interactions
Concomitant use of strong CYP3A4 inhibitors or inducers has the potential to affect the exposure to monomethyl auristatin E (MMAE).
Use in Specific Populations
Moderate or severe hepatic impairment or severe renal impairment: MMAE exposure and adverse reactions are increased. Avoid use.
Advise males with female sexual partners of reproductive potential to use effective contraception during ADCETRIS treatment and for at least 6 months after the final dose of ADCETRIS.
Advise patients to report pregnancy immediately and avoid breastfeeding while receiving ADCETRIS.